Akero Therapeutics, Inc. (AKRO)
AKRO moved a median of +0.03% 30 minutes after news, and -0.15% by the close. How AKRO actually reacts to news — the realized, point-in-time move the market made, measured across 838 labeled events over the last three years with zero look-ahead.
AKRO’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 47% | 810 |
| 30-min | +0.03% | 51% | 811 |
| 60-min | -0.15% | 45% | 811 |
| to close | -0.15% | 46% | 809 |
| Middle 50% of AKRO reactions | -0.87% to +0.75% |
|---|---|
| Median reaction (30-min) | +0.03% |
| Measured reactions | 838 |
Half of all Akero Therapeutics, Inc. news events land between -0.87% and +0.75% at 30 minutes.
Reaction stats as of 2026-08-31. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How AKRO reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 15 | -0.09% | 47% | -0.37% |
| Coverage initiations | 20 | -0.95% | 35% | +1.03% |
| Rating reiterations | 47 | -0.33% | 34% | -0.79% |
| Price-target raises | 11 | -0.33% | 18% | -3.33% |
Last 3 years, pulled 2026-08-31. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how AKRO ranks against every other measured name →
That’s how AKRO usually reacts — get an email when it moves on news →Email me when AKRO moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to AKRO's baseline. Nothing else.
Recent AKRO events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 15-12G Akero Therapeutics, Inc. | SEC filing · Form 15-12G | SEC EDGAR | — | — | |
| Form 8-K Akero Therapeutics, Inc. For: Dec 09 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form POSASR Akero Therapeutics, Inc. | SEC filing · Form POSASR | SEC EDGAR | — | — | |
| Form S-8 POS Akero Therapeutics, Inc. | SEC filing · Form S-8 | SEC EDGAR | — | — | |
| Form 8-K Akero Therapeutics, Inc. For: Dec 02 | SEC filing · Form 8-K | SEC EDGAR | +0.02% | +0.06% | |
| Form DEFA14A Akero Therapeutics, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.08% | +0.06% | |
| Halper Sadeh LLC Encourages WOW, AKRO, HFWA, BRY Shareholders to Contact the Firm to Discuss Their Rights | Press release | PR Newswire | -0.03% | -0.06% | |
| Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO) | Press release | PR Newswire | +0.00% | +0.02% | |
| Halper Sadeh LLC Encourages NIC, AKRO, BRNS Shareholders to Contact the Firm to Discuss Their Rights | Press release | PR Newswire | +0.00% | +0.01% | |
| Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting® 2025 | Press release | GlobeNewswire | +0.07% | +0.17% | |
| Form 10-Q Akero Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.08% | +0.09% | |
| Form DEFM14A Akero Therapeutics, Inc. | SEC filing · Form DEFM14A | SEC EDGAR | +0.00% | +0.07% | |
| Halper Sadeh LLC Encourages AKRO, CADE, FSUN Shareholders to Contact the Firm to Discuss Their Rights | Press release | PR Newswire | -0.01% | +0.07% | |
| Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO) | Press release | PR Newswire | +0.04% | +0.04% | |
| Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO) | Press release | PR Newswire | -0.18% | +0.33% | |
| Halper Sadeh LLC Encourages FFWM, AKRO, CCRD Shareholders to Contact the Firm to Discuss Their Rights | Press release | PR Newswire | +0.15% | +0.17% | |
| Form PREM14A Akero Therapeutics, Inc. For: Oct 24 | SEC filing · Form PREM14A | SEC EDGAR | -0.03% | -0.08% | |
| BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Akero Therapeutics, Inc. (Nasdaq - AKRO), CoreCard Corporation (NYSE - CCRD), PB Bankshares, Inc. (Nasdaq - PBBK), Air Lease Corporation (NYSE – AL) | Press release | GlobeNewswire | -0.22% | -0.07% | |
| BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Akero Therapeutics, Inc. (Nasdaq - AKRO), CoreCard Corporation (NYSE - CCRD), PB Bankshares, Inc. (Nasdaq - PBBK), Air Lease Corporation (NYSE – AL) | Press release | GlobeNewswire | +0.02% | +0.32% | |
| Akero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion | Press release | GlobeNewswire | -0.35% | -0.77% | |
| AKRO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Akero Therapeutics, Inc. Is Fair to Shareholders | Press release | Business Wire | -0.35% | -0.77% | |
| BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Akero Therapeutics, Inc. (Nasdaq - AKRO), CoreCard Corporation (NYSE - CCRD), PB Bankshares, Inc. (Nasdaq - PBBK), Air Lease Corporation (NYSE - AL) | Press release | GlobeNewswire | +0.02% | -0.19% | |
| Form 8-K Akero Therapeutics, Inc. For: Oct 08 | SEC filing · Form 8-K | SEC EDGAR | -0.03% | -0.37% | |
| Form DEFA14A Akero Therapeutics, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -0.03% | -0.37% | |
| Akero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting® 2025 | Press release | GlobeNewswire | +1.50% | +0.00% | |
| Form 8-K Akero Therapeutics, Inc. For: Sep 23 | SEC filing · Form 8-K | SEC EDGAR | +0.44% | -0.71% | |
| Akero Therapeutics to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference | Press release | GlobeNewswire | -0.58% | -2.41% | |
| Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH | Press release | GlobeNewswire | -2.81% | -0.04% | |
| Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | +1.41% | +1.41% | |
| Form 10-Q Akero Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.41% | +1.41% | |
| Form 8-K Akero Therapeutics, Inc. For: Aug 08 | SEC filing · Form 8-K | SEC EDGAR | +1.41% | +1.41% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.54% | -2.69% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | +1.51% | -0.64% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | +0.13% | -0.23% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.46% | -2.56% | |
| Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.88% | +3.26% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.20% | +0.73% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.12% | -0.71% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | -2.98% | +0.85% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | +1.45% | +1.32% | |
| Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.77% | +0.98% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.41% | -1.41% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | +0.53% | +1.56% | |
| Form 8-K Akero Therapeutics, Inc. For: Jun 03 | SEC filing · Form 8-K | SEC EDGAR | -0.07% | +2.14% | |
| Akero Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference | Press release | GlobeNewswire | +0.98% | +0.74% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | +0.00% | +0.94% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | +3.10% | +1.97% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.26% | +3.42% | |
| Akero Therapeutics to Present at the Jefferies Global Healthcare Conference | Press release | GlobeNewswire | +0.00% | -1.20% | |
| Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.90% | -2.83% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the AKRO section they belong to.
Where else AKRO is measured.
AKRO earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Akero Therapeutics, Inc.'s median reaction calculated?
Every labeled AKRO news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 838 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 51% of AKRO's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-08-31.
Does AKRO's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.